CVR 42093734Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)HinnerupFounded 1 Feb 2021
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about OncoSpear ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
8
CVR, Aug 2026
0 (0%) over 12 months
Gross profit
2.9M
DKK, annual report 2025
Result
-821.8K
DKK, annual report 2025
Equity
569.9K
DKK, annual report 2025
SPICA THERAPEUTICS100% of capital and votes
Operating company
Dandex estimate: 8 employees registered in 2026Niels Jonas Heilskov Graversensince 1 Feb 2021
Geert Gilbert Tackaertsince 30 Oct 2024
Owners of 5% or more. CVR registers shares in bands, not exact figures.
100% of capital and votesnotified 24 Oct 2024since 22 Aug 2024
CVR 305480945% to under 10% of capital and votesnotified 24 Oct 20241 Feb 2021 to 22 Aug 2024
CVR 305481675% to under 10% of capital and votesnotified 24 Oct 20241 Feb 2021 to 22 Aug 2024
CVR 306918065% to under 10% of capital and votesnotified 24 Oct 20241 Feb 2021 to 22 Aug 2024
CVR 3943271410% to under 15% of capital and votesnotified 24 Oct 20241 Feb 2021 to 22 Aug 2024
CVR 420124755% to under 10% of capital and votesnotified 24 Oct 20241 Feb 2021 to 22 Aug 2024
5% to under 10% of capital and votesnotified 5 Oct 20221 Feb 2021 to 22 Aug 2024
50% to under 66.7% of capital and votesnotified 29 Dec 202330 Sep 2022 to 22 Aug 2024
Founded 1 Feb 2021.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 8 employees, 5 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 6 | 7 | 7 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 7 | 5 | 5 | 6 | 7 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| FTE | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 5 | 5 | 5 | 5 | 5 | 3 | 3 | 5 | 4 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 6 | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 5 | 5 | 5 | 6 | 5 | 5 | 5 | 6 | 6 | 5 | 5 | 5 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit 2.9M, Operating profit -1M, Result for the year -821.8K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 9.5M, Equity 569.9K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -26 | -640 | -5,396 | -4,652 | 2,927 |
| Operating profit | Not reported | -1,228 | -8,147 | -8,041 | -1,005 |
| Result for the year | -26 | -1,090 | -6,694 | -6,461 | -822 |
| Equity | 24 | 7,112 | 7,853 | 1,392 | 570 |
| Total assets | 33 | 7,510 | 9,253 | 3,251 | 9,511 |
| Employees (average) | Not reported | 1 | 5 | 5 | 5 |
Not every period is a full year: 2021 covers 11 months (1 Feb to 31 Dec 2021). Changes against it compare periods of different length.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | Not reportednote 1 | n.m.note 2 | 400% | 0% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
What Pro holds for OncoSpear ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 3,717,472, cash price 334.58, implied value 36,431,624 | 334.58 | 3,717,472 | 36,431,624 | 108,889 | |
| IncreaseCashPaid in 3,717,472, cash price 334.58, implied value 32,714,153 | 334.58 | 3,717,472 | 32,714,153 | 97,778 | |
| IncreaseCashPaid in 8,178,439, cash price 223.05, implied value 19,330,754 | 223.05 | 8,178,439 | 19,330,754 | 86,667 | |
| FoundingCashPaid in 50,000 | None | 50,000 | None | 50,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
10 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: c/o Anders Etzerodt, Lucernevej 2, 8382 Hinnerup
Ny kommune: Favrskov
Ny adresse: c/o Jonas Graversen, Sanatorievej 8, 5600 Faaborg
Ny kommune: Faaborg-Midtfyn
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 06.03.2025.
Tiltrådte:
CVR-NR. 38751646 KOVSTED & SKOVGÅRD, REVISION & RÅDGIVNING, STATSAUTORISERET REVISIONSPARTNERSELSKAB, Brunbjergvej 3, 8240 Risskov, den 06.03.2025.
Vedtægter ændret: 30.10.2024
Bestyrelse:
Fratrådte:
Anders Etzerodt, den 30.10.2024, Søren Kragh Moestrup, den 30.10.2024, Holger Jon Møller, den 30.10.2024, Alexander Bharmal Demoulin, den 30.10.2024, Debora Catharina Dumont, (formand), den 30.10.2024, Toby Lawrence, den 30.10.2024.
Direktion:
Tiltrådte:
Geert Gilbert Tackaert, den 30.10.2024.
Selskabet tegnes af den samlede direktion
Vedtægter ændret: 20.12.2023
Kapitalforhøjelsen er besluttet den 20.12.2023.
kr. 11.111,00, indbetalt kontant, kurs 33.457,58.
Kapitalen udgør herefter kr. 108.889,00.
Vedtægter ændret: 27.06.2023
Kapitalforhøjelsen er besluttet den 27.06.2023.
kr. 11.111,00, indbetalt kontant, kurs 33.457,58.
Kapitalen udgør herefter kr. 97.778,00.
Bestyrelse:
Fratrådte:
Jens Kristian Damsgaard, den 27.06.2023.
Revision:
Tiltrådte:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Munkebjergvænget 1, 3., 5230 Odense M, den 22.06.2023.
Bestyrelse:
Fratrådte:
Søren Kragh Moestrup, (formand), den 02.01.2023, Debora Catharina Dumont, den 02.01.2023.
Tiltrådte:
Søren Kragh Moestrup, den 02.01.2023, Debora Catharina Dumont, (formand), den 02.01.2023.
Vedtægter ændret: 30.09.2022
Kapitalforhøjelsen er besluttet den 30.09.2022.
kr. 36.667,00, indbetalt kontant, kurs 22.304,63.
Kapitalen udgør herefter kr. 86.667,00.
Bestyrelse:
Tiltrådte:
Alexander Bharmal Demoulin, den 30.09.2022, Debora Catharina Dumont, den 30.09.2022.
Selskabet tegnes af bestyrelsesformanden sammen med en direktør, af bestyrelsesformanden sammen med et andet bestyrelsesmedlem eller af den samlede bestyrelse
Formål ændret: Selskabets formål er at udvikle, markedsføre, licensere og sælge lægemidler, herunder at udvikle en forskningsplatform, der vil blive brugt til at identificere receptorer, der kan binde til lægemiddelkandidater, samt dermed beslægtede aktiviteter.
Stiftelsesdato: 01.02.2021.
Seneste vedtægtsdato: 01.02.2021.
Kapital:
kr. 50.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 50.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
Toby Lawrence, den 01.02.2021, CVR-NR. 30548094 MOESTRUP HOLDING 2007 ApS, Jørgen Brønlunds Vej 14, 8200 Aarhus N, den 01.02.2021, CVR-NR. 30548167 MØLLER HOLDING 2007 ApS, Hørmarks Allé 8, 8240 Risskov, den 01.02.2021, CVR-NR. 30691806 PHIDEAS ApS, Tesdorpfsvej 12, 5000 Odense C, den 01.02.2021, CVR-NR. 39432714 DeLiver Pharma ApS, Tesdorpfsvej 12, 5000 Odense C, den 01.02.2021, CVR-NR. 42012475 Etze Holding ApS, Lucernevej 2, 8382 Hinnerup, den 01.02.2021.
Bestyrelse:
Søren Kragh Moestrup, (formand), den 01.02.2021, Jens Kristian Damsgaard, den 01.02.2021, Anders Etzerodt, den 01.02.2021, Holger Jon Møller, den 01.02.2021, Toby Lawrence, den 01.02.2021.
Direktion:
Niels Jonas Heilskov Graversen, den 01.02.2021.
Selskabet tegnes af en direktør og bestyrelsesformanden i forening eller af den samledebestyrelse i forening.
Første regnskabsår:
01.02.2021 - 31.12.2021.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at udvikle lægemidler til behandling af cancer samt enhver virksomhed i hermed stående forbindelse.
P-number 1026768736Lucernevej 2, 8382 Hinnerup
No other current company drawn.